Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105324 | 1.00 | P2RX7 (0.42) | P2RX7HCRTR1HCRTR2F2CHRNB4 | |
| SCHEMBL9103984 | 0.86 | HCRTR1 (0.44) | HCRTR1HCRTR2MET | |
| SCHEMBL9103980 | 0.86 | HCRTR1 (0.44) | HCRTR1HCRTR2MET | |
| SCHEMBL1241492 | 0.85 | HCRTR1 (0.40) | HCRTR1HCRTR2CHRNB4CHRNA3MET | |
| SCHEMBL1241494 | 0.85 | HCRTR1 (0.40) | HCRTR1HCRTR2CHRNB4CHRNA3MET | |
| SCHEMBL9103418 | 0.84 | HCRTR1 (0.44) | HCRTR1HCRTR2CHRNB4CHRNA3MET | |
| SCHEMBL9103413 | 0.84 | HCRTR1 (0.44) | HCRTR1HCRTR2CHRNB4CHRNA3MET | |
| SCHEMBL9281079 | 0.82 | HTR7 (0.43) | HCRTR1HCRTR2CHRNB4CHRNA3MET | |
| SCHEMBL9281080 | 0.82 | HTR7 (0.43) | HCRTR1HCRTR2CHRNB4CHRNA3MET | |
| SCHEMBL9102305 | 0.80 | HCRTR1 (0.43) | HCRTR1HCRTR2CHRNB4CHRNA3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969383-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809380-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | P2RX7 183/4885HCRTR1 471/4885HCRTR2 356/4885 |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | P2RX7 183/4885HCRTR1 471/4885HCRTR2 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.